Published in Cell Death Dis on January 24, 2013
Upregulation of microRNA135a-3p and death receptor 5 plays a critical role in Tanshinone I sensitized prostate cancer cells to TRAIL induced apoptosis. Oncotarget (2014) 0.93
Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. Clin Lymphoma Myeloma Leuk (2015) 0.78
Silencing of survivin by YM155 induces apoptosis and growth arrest in hepatocellular carcinoma cells. Oncol Lett (2015) 0.77
Delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5 and causing caspase-mediated HDAC3 cleavage. Oncotarget (2015) 0.77
Farnesylthiosalicylic acid sensitizes hepatocarcinoma cells to artemisinin derivatives. PLoS One (2017) 0.75
Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities. Acta Biochim Biophys Sin (Shanghai) (2015) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Hepatocellular carcinoma. N Engl J Med (2011) 19.40
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology (2006) 3.95
Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res (2008) 3.92
Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther (2005) 3.27
To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest (2008) 3.05
Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest (2007) 2.53
Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem (2004) 1.88
Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol (2009) 1.81
Following TRAIL's path in the immune system. Immunology (2009) 1.60
Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res (2009) 1.51
Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res (2010) 1.50
A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res (2008) 1.44
Targeting survivin in cancer: the cell-signalling perspective. Drug Discov Today (2011) 1.40
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol (2009) 1.33
Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells. Mol Cancer Ther (2007) 1.31
Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid. J Biol Chem (1995) 1.25
Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways. J Gastroenterol Hepatol (2011) 1.11
Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid). Cancer Res (2007) 1.05
Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer Chemother Pharmacol (2010) 1.02
Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. Cancer Lett (2008) 0.99
Relationship between survivin expression and recurrence, and prognosis in hepatocellular carcinoma. World J Gastroenterol (2007) 0.96
Comparison of four different colorimetric and fluorometric cytotoxicity assays in a zebrafish liver cell line. BMC Pharmacol (2008) 0.96
Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis. Mol Cancer Ther (2006) 0.95
Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy. Int J Cancer (2011) 0.95
Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. Mol Cancer (2010) 0.93
FTS and 2-DG induce pancreatic cancer cell death and tumor shrinkage in mice. Cell Death Dis (2012) 0.92
The role of K-ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines. Cancer Chemother Pharmacol (2010) 0.84
Survivin antisense compound inhibits proliferation and promotes apoptosis in liver cancer cells. World J Gastroenterol (2005) 0.83
The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats. Eur J Cancer (2009) 0.82
Inhibition of the Ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats. Clin Sci (Lond) (2008) 0.80
Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis. Mol Carcinog (2011) 0.80
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat (2014) 2.23
Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol (2001) 1.79
Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol (2001) 1.72
Hepatic perfusion parameters in chronic liver disease: dynamic CT measurements correlated with disease severity. AJR Am J Roentgenol (2001) 1.70
Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat (2014) 1.68
Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat (2014) 1.67
Somatic mutation in human T-cell leukemia virus type 1 provirus and flanking cellular sequences during clonal expansion in vivo. J Natl Cancer Inst (2001) 1.64
Venlafaxine-associated hepatitis. Ann Intern Med (1999) 1.60
Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin. Lancet (1999) 1.59
HLA association of amoxicillin-clavulanate--induced hepatitis. Gastroenterology (1999) 1.56
High circulating proviral load with oligoclonal expansion of HTLV-1 bearing T cells in HTLV-1 carriers with strongyloidiasis. Oncogene (2000) 1.54
Assessment of hepatic perfusion parameters with dynamic MRI. Magn Reson Med (2002) 1.47
Pruritus associated with cholestatic liver disease. Ann Intern Med (1996) 1.40
The monoethylglycinexylidide test does not correctly evaluate lidocaine metabolism after ischemic liver injury in the rat. Hepatology (1997) 1.39
Adult-to-adult living related liver transplantation: initial experience. Acta Gastroenterol Belg (2001) 1.37
Non-invasive quantification of liver perfusion with dynamic computed tomography and a dual-input one-compartmental model. Clin Sci (Lond) (2000) 1.31
Oligofructose promotes satiety in healthy human: a pilot study. Eur J Clin Nutr (2006) 1.30
Eosinophilic gastroenteritis presenting with colitis and cholangitis. Dig Dis Sci (1995) 1.29
Persistent oligoclonal expansion of human T-cell leukemia virus type 1-infected circulating cells in patients with Tropical spastic paraparesis/HTLV-1 associated myelopathy. Oncogene (1998) 1.28
Symptomatic myopathy in hepatitis C infection without interferon therapy. Lancet (1995) 1.08
Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet (1996) 1.07
Altered expression of hepatic CYP2E1 and CYP4A in obese, diabetic ob/ob mice, and fa/fa Zucker rats. Biochem Biophys Res Commun (1999) 1.06
Adult polycystic liver disease: is fenestration the most adequate operation for long-term management? Ann Surg (1997) 1.06
Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther (2002) 1.05
Disposable versus reusable biopsy forceps: a prospective cost evaluation. Gastrointest Endosc (2000) 1.05
The surgical management of congenital liver cysts. Surg Endosc (2001) 1.05
Focal nodular hyperplasia: natural course observed with CT and MRI. J Comput Assist Tomogr (2000) 1.05
Inflammatory pseudotumor of the liver: MRI with mangafodipir trisodium. J Comput Assist Tomogr (1998) 1.03
Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. Eur J Clin Nutr (2005) 0.97
Liver injury related to amoxycillin-clavulanic acid: interlobular bile-duct lesions and extrahepatic manifestations. J Hepatol (1995) 0.96
The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver. Eur J Cancer (2007) 0.94
Haptoglobin phenotype 2-2 overrepresentation in Cys282Tyr hemochromatotic patients. J Hepatol (2001) 0.93
Severe radiation-induced liver disease following localized radiation therapy for biliopancreatic carcinoma: activation of hepatic stellate cells as an early event. Hepatology (1997) 0.93
Alcohol dependence is associated with reduced plasma and fundic ghrelin levels. Eur J Clin Invest (2008) 0.93
Tamoxifen-induced steatohepatitis. Ann Intern Med (1996) 0.93
Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation. J Hepatol (1998) 0.92
Influence of body mass index, sex and age on serum alanine aminotransferase (ALT) level in healthy blood donors. Acta Gastroenterol Belg (1999) 0.92
Lamivudine for nephrotic syndrome related to hepatitis B virus (HBV) infection. Clin Nephrol (2006) 0.90
Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats. Gut (2006) 0.89
Favorable outcome of orthotopic liver transplantation in a patient with subacute liver failure due to the emergence of a hepatitis B YMDD escape mutant virus. J Hepatol (2001) 0.88
[Vascular gastric anomalies, CREST syndrome and primary biliary cirrhosis: efficacy of ethinyl estradiol-norethisterone combination]. Gastroenterol Clin Biol (1994) 0.88
Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress. Clin Pharmacol Ther (1998) 0.86
Watermelon stomach. An unusual cause of recurrent upper GI tract bleeding in the uraemic patient: efficient treatment with oestrogen-progesterone therapy. Nephrol Dial Transplant (1996) 0.85
Effect of hepatic insufficiency on pharmacokinetics and drug dosing. Pharm World Sci (1998) 0.85
Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days. Atherosclerosis (1996) 0.84
A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C. J Viral Hepat (2007) 0.84
Estimation of chlorzoxazone hydroxylase activity in liver microsomes and of the plasma pharmacokinetics of chlorzoxazone by the same high-performance liquid chromatographic method. J Chromatogr A (1998) 0.83
Role of dietary iron in maturation of rat small intestine at weaning. Am J Physiol (1984) 0.83
Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients. Clin Biochem (2011) 0.83
Hypervitaminosis A-induced liver fibrosis: stellate cell activation and daily dose consumption. Liver Int (2006) 0.83
A pharmacokinetic evaluation of the second-generation H1-receptor antagonist cetirizine in very young children. Clin Pharmacol Ther (1993) 0.83
The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats. Eur J Cancer (2009) 0.82
Differential activities of CYP1A isozymes in hepatic and intestinal microsomes of control and 3-methylcholanthrene-induced rats. Pharmacol Toxicol (2000) 0.81
Multisystemic sarcoidosis associated with a second therapy for chronic hepatitis C. Acta Gastroenterol Belg (2009) 0.81
Subfulminant hepatitis requiring liver transplantation following ibuprofen overdose. Liver (2000) 0.81
Pharmacokinetic-pharmacodynamic relationships of H1-antihistamines. Clin Pharmacokinet (1995) 0.81
Sensitive assay for midazolam and its metabolite 1'-hydroxymidazolam in human plasma by capillary high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl (1998) 0.81
[Adenoid cystic carcinoma. Apropos of a case localized in the lacrimal apparatus]. Ann Otolaryngol Chir Cervicofac (1994) 0.81
Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine. J Lab Clin Med (2000) 0.81
The compensatory hyperplasia (liver regeneration) following ligation of a portal branch is initiated before the atrophy of the deprived lobes. J Hepatol (2000) 0.81
Detection and segmental location of malignant hepatic tumors: comparison of ferumoxides-enhanced gradient-echo and T2-weighted spin-echo MR imaging. AJR Am J Roentgenol (1997) 0.80
Is antiviral treatment (IFN alpha and/or ribavirin) justified in cirrhosis related to hepatitis C virus? Société Royale Belge de Gastro-entérologie. Acta Gastroenterol Belg (1999) 0.80
Liver abscesses due to Fusobacterium species. Liver (2000) 0.80
Dietary restriction of energy and sugar results in a reduction in human cytochrome P450 2E1 activity. Br J Nutr (1999) 0.80
Fast determination of low-level cytochrome P-450 1A1 activity by high-performance liquid chromatography with fluorescence or visible absorbance detection. J Chromatogr B Biomed Appl (1996) 0.80
Intravenous omeprazole in critically ill patients: a randomized, crossover study comparing 40 with 80 mg plus 8 mg/hour on intragastric pH. Crit Care Med (2001) 0.80
Pharmacogenetics of human erythrocyte thiopurine methyltransferase activity in a French population. Br J Clin Pharmacol (1991) 0.80
Meloxicam-induced liver toxicity. Acta Gastroenterol Belg (1999) 0.80
Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models. Acta Gastroenterol Belg (2011) 0.79
Expression of presumed specific early and late factors associated with liver regeneration in different rat surgical models. Lab Invest (2001) 0.79
High 6-thioguanine nucleotide levels and low thiopurine methyltransferase activity in patients with lupus erythematosus treated with azathioprine. Am J Ther (2001) 0.79
Severe acute cholestatic hepatitis with prolonged cholestasis and bile-duct injury following atorvastatin therapy: a case report. Acta Gastroenterol Belg (2009) 0.79
Midazolam and cortisol metabolism before and after CYP3A induction in humans. Int J Clin Pharmacol Ther (2001) 0.79
Transjugular liver biopsy. An experience based on 500 procedures. Acta Gastroenterol Belg (1997) 0.78
Endoscopic band ligation: a safe technique to control bleeding esophageal varices in pregnancy. Gastrointest Endosc (1998) 0.78
After portal branch ligation in the rat, cellular proliferation is associated with selective induction of c-Ha-ras, p53, cyclin E, and Cdk2. Gut (2001) 0.78
CYP 3A proteins are expressed in human neutrophils and lymphocytes but are not induced by rifampicin. Life Sci (1999) 0.78
Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial. J Viral Hepat (2003) 0.78
Lamivudine inhibits hepatitis B virus replication in kidney graft recipients. Transplantation (1998) 0.78
Effectiveness and tolerability of pegylated interferon alfa-2b in combination with ribavirin for treatment of chronic hepatitis C: the PegIntrust study. Acta Gastroenterol Belg (2010) 0.78
Dramatic response after an intravenous loading dose of azathioprine in one case of severe and refractory ankylosing spondylitis. Rheumatology (Oxford) (2000) 0.78
Subfulminant hepatitis requiring liver transplantation after benzarone administration. J Hepatol (1994) 0.78
The management of patients with mild hepatitis C. Acta Gastroenterol Belg (2005) 0.78
Failure of ribavarin or immunosuppressive therapy to alter the course of post-infantile giant-cell hepatitis. J Hepatol (1995) 0.77
Guidelines for the management of chronic hepatitis C in patients infected after substance use. Acta Gastroenterol Belg (2005) 0.77